- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer () - Mar 31, 2024 - Abstract #SWOGSpring2024SWOG_Spring_41;
Two participants on the Nivolumab + Encorafenib + Cetuximab arm have experienced Grade 4 events, including colitis, colonic perforation, and hypertension. No Grade 4 or 5 events have been reported on the Encorafenib + Cetuximab arm.
- |||||||||| BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Mar 26, 2024
P1, N=47, Active, not recruiting,
Phase classification: P2 --> P1 | N=82 --> 12 Recruiting --> Active, not recruiting
- |||||||||| metformin / Generic mfg.
Journal: Anti-ENO1 antibody combined with metformin against tumor resistance: a novel antibody-based platform. (Pubmed Central) - Mar 26, 2024
The study preliminarily revealed anti-ENO1 antibody combined with metformin could overcome drug resistance against CSCs by inhibiting the Wnt//?-catenin pathway and might serve as a potential precursor platform for screening ADC. More importantly, it is reasonably believed that antibody-based drug combination therapy might function as an encouraging tool for oncotherapy.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, HEOR, PD(L)-1 Biomarker, IO biomarker, Cost-effectiveness, Cost effectiveness, Metastases: Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis. (Pubmed Central) - Mar 26, 2024
Importantly, there was heterogeneity in the cost-effectiveness probabilities, based on primary sites and expression levels of PD-L1. Therefore, tailored treatment based on individual patient and clinical characteristics, remains important, and may impact the cost-effectiveness of the regimens under study.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov) - Mar 25, 2024
P2, N=34, Recruiting,
Therefore, tailored treatment based on individual patient and clinical characteristics, remains important, and may impact the cost-effectiveness of the regimens under study. Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, ulixertinib (BVD-523) / BioMed Valley Discoveries, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Combination therapy, Metastases: Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy (clinicaltrials.gov) - Mar 25, 2024
P1, N=27, Recruiting,
This strategy might be expected to concomitantly trigger the crosstalk of adaptive immune response leading to a complementing T cell immune rejection of tumors. Suspended --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy. (Pubmed Central) - Mar 22, 2024
Additionally, both mouse and human orthotopic tumor models exhibited the selective tumor-targeting efficacy of AGCM-22, along with favorable metabolic properties and superior anti-GBM activity compared to temozolomide (TMZ). In summary, this study presents a novel ADC for GBM therapy that utilizes cetuximab as the tumor-targeting antibody, resulting in effective delivery of the cytotoxic drug payload.
- |||||||||| Trial completion date, Trial primary completion date, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Mar 21, 2024
P3, N=400, Recruiting,
In summary, this study presents a novel ADC for GBM therapy that utilizes cetuximab as the tumor-targeting antibody, resulting in effective delivery of the cytotoxic drug payload. Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2026
- |||||||||| Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 21, 2024
P1, N=33, Active, not recruiting,
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
- |||||||||| Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 21, 2024
P2, N=198, Recruiting,
Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2026 Active, not recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Near-Infrared Fluorescence Imaging Sensor with Laser Diffuser for Visualizing Photoimmunotherapy Effects under Endoscopy. (Pubmed Central) - Mar 17, 2024
This device was employed to demonstrate that a laser diffuser with an NIR fluorescence imaging sensor could be delivered through a 3.2 mm diameter port. In addition, fluorescence images of Cetuximab-IR700 were successfully observed in two mice, and the fluorescence intensity confirmed that the fluorescence decayed within 330 s. This device is expected to have practical application as a tool to identify the optimal irradiation dose for tumor-selective photosensitive substances under endoscopy.
- |||||||||| Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 15, 2024
P1/2, N=27, Active, not recruiting,
In addition, fluorescence images of Cetuximab-IR700 were successfully observed in two mice, and the fluorescence intensity confirmed that the fluorescence decayed within 330 s. This device is expected to have practical application as a tool to identify the optimal irradiation dose for tumor-selective photosensitive substances under endoscopy. Trial primary completion date: Sep 2022 --> Mar 2024
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
EXPLORING THE GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC INTERSECTIONS IN CHOLANGIOCARCINOMA: A DRUG DISCOVERY APPROACH (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3118;
FDA-approved and experimental drugs are available that interact with many of these targets, offering potential therapeutic benefits for patients with CCA. This underscores the unparalleled opportunity offered by the computational biology to explore and discover multi-omics targets with promising therapeutic potentials, while saving time and cost.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
USE OF DEEP LEARNING TO EVALUATE TUMOR MORPHOLOGICAL FEATURES FOR PREDICTION OF COLON CANCER RECURRENCE (152AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_362;
A deep learning algorithm (QuantCRC) applied to routine colon cancer sections enhances interpretive accuracy by identifying distinct morphological features driving patient prognosis within MMR groups. Our independently validated results can enable patient risk stratification for recurrence.
- |||||||||| Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (clinicaltrials.gov) - Mar 14, 2024
P3, N=461, Active, not recruiting,
Our independently validated results can enable patient risk stratification for recurrence. Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2025
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, urelumab (BMS-663513) / BMS, Ono Pharma
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. (Pubmed Central) - Mar 13, 2024
P1/2, P1b
Although the addition of urelumab at these doses was tolerable, preliminary response rates did not indicate an evident additive benefit. Nevertheless, the positive pharmacodynamics effects observed with urelumab and the high response rate in treatment-naive patients with melanoma warrant further investigation of other anti-CD137 agonist agents for treatment of cancer.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open, Trial completion date, Trial primary completion date, Metastases: Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (clinicaltrials.gov) - Mar 12, 2024
P2, N=120, Recruiting,
Given the variation in prognoses, TTRI should be considered a stratification factor in future clinical trials. Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2030 | Trial primary completion date: Dec 2020 --> Dec 2030
- |||||||||| ZEN-3694 / Zenith Capital Corp, Erbitux (cetuximab) / Eli Lilly, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (clinicaltrials.gov) - Mar 12, 2024
P1, N=30, Recruiting,
Unknown status --> Recruiting | Trial completion date: Dec 2021 --> Dec 2030 | Trial primary completion date: Dec 2020 --> Dec 2030 Not yet recruiting --> Recruiting | N=22 --> 30 | Trial completion date: Jun 2024 --> Jun 2025 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 12, 2024
P3, N=464, Active, not recruiting,
Not yet recruiting --> Recruiting | N=22 --> 30 | Trial completion date: Jun 2024 --> Jun 2025 | Initiation date: Feb 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Jun 2025 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2024 | Trial primary completion date: Jun 2021 --> Jul 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal, Metastases: The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. (Pubmed Central) - Mar 11, 2024
In our systematic review, we revised available data from clinical trials assessing anti-EGFR rechallenge activity in chemo-refractory mCRC patients, discussing as well potential future scenarios and development to implement this therapeutic approach. Particularly, we discussed the role of ctDNA as a safe, timely and comprehensive tool to refine patient's selection and the therapeutic index of anti-EGFR rechallenge.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Patient Journey of Head & Neck Squamous Cell Cancer in Oncology Centers in Colombia () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1090;
While the treatment patterns were aligned with the established guidelines, the DI and TI showed delays, particularly affecting to the CR, highlighting the need of actions that improve diagnosis and treatment in HNSCC. Future research should focus on exploring the causes of these delays and evaluating targeted interventions in reducing them.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retro-odontoid Pseudotumor Mimicking Acute Stroke Symptoms (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3265;
REB and RP provided large uncertainty, likely due to their strong assumption of exchangeable referent treatment. 65-year-old male with history of HTN, HLD, non-obstructive CAD, NSTEMI, bilateral carotid stenosis status post right carotid stent and transcarotid artery revascularization procedure, squamous cell carcinoma of tonsil and neck status post head and neck surgery, chemotherapy with Erbitux and radiation(in remission), scoliosis, and chronic neck and lower back pain who presented with right sided weakness, numbness and slurred speech for 3 hours, patient received thrombolytic therapy and was transferred to neuro-ICU...Although there may be high suspicion of stroke given strong risk factors but we need to keep in mind structural abnormalities that may explain symptoms in patients with negative imaging and can consider this presentation as a possible stroke mimic.
|
